• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NRG-BR008/HERO研究：一项针对低风险HER2阳性乳腺癌放疗优化的III期随机试验。

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.

作者信息

Braunstein Lior Z, Mitchell Melissa P, Bandos Hanna, Sikov William M, Khan Atif J, Chen Peter Y, Ganz Patricia A, Jagsi Reshma, White Julia R, Cecchini Reena S, Kang Hyejoo, Puhalla Shannon L, Bolton Kelly L, Connolly Eileen P, Stringer-Reasor Erica M, Gergelis Kimberly R, Julian Thomas B, Mamounas Eleftherios P, Wolmark Norman

机构信息

Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Future Oncol. 2025 Jul;21(16):2017-2025. doi: 10.1080/14796694.2025.2511586. Epub 2025 Jun 26.

DOI:10.1080/14796694.2025.2511586
PMID:40574381
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12218515/
Abstract

NCT05705401 (ClinicalTrials.gov).

摘要

NCT05705401（临床试验.gov）。

相似文献

1
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.NRG-BR008/HERO研究：一项针对低风险HER2阳性乳腺癌放疗优化的III期随机试验。
Future Oncol. 2025 Jul;21(16):2017-2025. doi: 10.1080/14796694.2025.2511586. Epub 2025 Jun 26.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
3
Trastuzumab-containing regimens for metastatic breast cancer.用于转移性乳腺癌的含曲妥珠单抗方案。
Cochrane Database Syst Rev. 2014 Jun 12;2014(6):CD006242. doi: 10.1002/14651858.CD006242.pub2.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.用于早期乳腺癌辅助治疗的INTRABEAM®光子放射治疗系统：系统评价与经济评估
Health Technol Assess. 2015 Aug;19(69):1-190. doi: 10.3310/hta19690.
8
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.一项评价皮下注射 CpG 寡脱氧核苷酸（PF03512676）联合曲妥珠单抗治疗转移性 HER2+乳腺癌患者的开放性研究。
Cancer Control. 2024 Jan-Dec;31:10732748241250189. doi: 10.1177/10732748241250189.
9
Sexual Harassment and Prevention Training性骚扰与预防培训
10
Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation.侵入性尿动力学检查在难治性膀胱过度活动症女性患者管理中的应用：FUTURE，一项优效性随机对照试验及经济学评估
Health Technol Assess. 2025 Jul;29(27):1-139. doi: 10.3310/UKYW4923.

本文引用的文献

1
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.曲妥珠单抗美坦新偶联物对比紫杉醇联合曲妥珠单抗用于人表皮生长因子受体 2 阳性Ⅰ期乳腺癌：来自 ATEMPT 的 5 年结果和相关分析
J Clin Oncol. 2024 Nov;42(31):3652-3665. doi: 10.1200/JCO.23.02170. Epub 2024 Jun 27.
2
Health Care Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents.转移性乳腺癌患者新接受人表皮生长因子受体 2（HER2）靶向药物治疗的医疗资源利用和费用。
Clin Breast Cancer. 2022 Jun;22(4):e488-e496. doi: 10.1016/j.clbc.2021.11.013. Epub 2021 Dec 2.
3
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).小淋巴结阴性、HER2 阳性乳腺癌女性的局部区域复发：一项前瞻性多机构研究（APT 试验）的结果。
Breast Cancer Res Treat. 2019 Jul;176(2):303-310. doi: 10.1007/s10549-019-05238-4. Epub 2019 Apr 19.
4
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.辅助紫杉醇和曲妥珠单抗治疗淋巴结阴性、人表皮生长因子受体 2 阳性乳腺癌的 7 年随访分析。
J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2.
5
Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?随机临床试验中的替代终点和中间终点：目标是什么？
Clin Cancer Res. 2018 May 15;24(10):2239-2240. doi: 10.1158/1078-0432.CCR-18-0183. Epub 2018 Feb 12.
6
Radiation costing methods: a systematic review.放射治疗成本核算方法：一项系统综述。
Curr Oncol. 2016 Aug;23(4):e392-408. doi: 10.3747/co.23.3073. Epub 2016 Aug 12.
7
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.65 岁或以上早期乳腺癌女性中保乳手术联合或不联合放疗（PRIME II）：一项随机对照试验。
Lancet Oncol. 2015 Mar;16(3):266-73. doi: 10.1016/S1470-2045(14)71221-5. Epub 2015 Jan 28.
8
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.放射治疗肿瘤学组（RTOG）9804：一项针对低风险导管原位癌的前瞻性随机试验，比较放疗与观察的效果。
J Clin Oncol. 2015 Mar 1;33(7):709-15. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20.
9
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.辅助性紫杉醇和曲妥珠单抗用于HER2阳性、淋巴结阴性乳腺癌的治疗
N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281.
10
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.早期乳腺癌且年龄 70 岁及以上的女性行保乳手术加他莫昔芬与或不加放疗：CALGB 9343 的长期随访结果
J Clin Oncol. 2013 Jul 1;31(19):2382-7. doi: 10.1200/JCO.2012.45.2615. Epub 2013 May 20.